What is the IVDR and how does it affect IVD marketing?

The IVDR (EU 2017/746) is the European Union's In Vitro Diagnostic Regulation, replacing the former IVDD directive. It fundamentally changes IVD classification, clinical evidence requirements, and market access procedures. Under the IVDD, approximately 80% of IVDs were self-certified. Under the IVDR, roughly 80% now require Notified Body assessment. For marketing, this means claims must be precisely aligned with clinical evidence submitted to Notified Bodies, compliance status becomes a marketable differentiator, and content strategies must address new regulatory realities for laboratory customers.

How does the IVDR classification system differ from the IVDD?

The IVDD used a simple list-based approach where Annex II listed higher-risk devices and everything else was largely self-certified. The IVDR introduces a risk-based classification with four classes: Class A (lowest risk, general lab devices), Class B (moderate risk, routine clinical testing), Class C (higher risk, blood typing, companion diagnostics, infectious disease screening), and Class D (highest risk, blood screening for HIV, hepatitis, transfusion blood grouping). This shift dramatically increases the proportion of devices requiring Notified Body involvement and creates new clinical evidence obligations.

How can diagnostic companies use IVDR compliance as a marketing advantage?

Companies achieving full IVDR compliance ahead of competitors can differentiate through several strategies: prominently communicating IVDR certification status as a quality signal for European procurement teams; positioning robust clinical performance studies as evidence leadership; providing continuity assurance to laboratories concerned about supply disruption as competitors lose legacy certifications; and transparently communicating classification, CE marking status, and Notified Body information to build trust with sophisticated buyers who understand the regulatory landscape.

What content marketing strategies work for IVDR markets?

Four content types are particularly effective: regulatory education content helping laboratory professionals understand IVDR implications (reclassification effects, LDT requirements, supplier evaluation criteria); accessible clinical evidence summaries demonstrating product performance; regular transition timeline communications updating customers on your IVDR compliance status across your product portfolio; and comparison and selection guides that help laboratories evaluate IVDs using IVDR-aligned criteria like clinical performance data quality and post-market surveillance commitments.

How does the IVDR affect companion diagnostic marketing?

Under the IVDR, companion diagnostics are classified as Class C devices requiring Notified Body assessment with specific attention to the drug-diagnostic linkage. Marketing messaging must clearly communicate approved drug-diagnostic pairings, clinical evidence must include the diagnostic's performance in the context of drug clinical trials, promotional materials must be coordinated with pharmaceutical marketing teams for consistency, and IVDR compliance timelines for companion diagnostics may affect drug launch strategies in European markets.

What is the Notified Body bottleneck and how does it affect marketing?

As of early 2026, fewer than 10 Notified Bodies are fully designated for IVDR assessments, compared to over 20 under the IVDD. This bottleneck creates real market access challenges. Companies with established Notified Body relationships can bring products to market faster, and this speed advantage is marketable. Competitors facing delays may have portfolio gaps, creating market share opportunities. Communicating your Notified Body relationship and assessment timeline provides procurement confidence to European laboratory customers evaluating supply reliability.

How should marketing teams prepare for EUDAMED?

The European Database on Medical Devices (EUDAMED) will make device registration, certificates, clinical investigation data, vigilance reports, and market surveillance information publicly accessible. Marketing teams should ensure all information in EUDAMED is accurate and aligned with marketing claims, since discrepancies will be visible to competitors and customers. Proactive transparency through making your EUDAMED data well-organized and easily accessible can be a trust differentiator. Competitors' regulatory status and vigilance history will also be visible, enabling more informed competitive positioning.

How do you manage marketing claims under the IVDR?

Every marketing claim must be traceable to supporting clinical evidence in the technical documentation. Establish a claims matrix mapping marketing messages to specific evidence sources. Update promotional material review processes to include IVDR-specific checkpoints: classification accuracy, CE marking display, UDI compliance, and alignment with the declared intended purpose. Invest in training so marketing professionals understand the IVDR framework well enough to create compliant materials. Use digital asset management systems that maintain version-controlled materials aligned with current regulatory status.

IVDR Marketing Strategy: Navigating the EU IVD Regulation

The IVDR Landscape: A Regulatory Earthquake for Diagnostic Companies

The European Union's In Vitro Diagnostic Regulation (EU 2017/746), commonly referred to as the IVDR, represents the most significant regulatory overhaul of the diagnostic industry in over two decades. Replacing the In Vitro Diagnostic Medical Devices Directive (IVDD 98/79/EC), the IVDR fundamentally changes how in vitro diagnostic devices are classified, assessed, and marketed across the European Economic Area.

For diagnostic companies, the IVDR is not merely a compliance exercise. It is a strategic inflection point that affects product development timelines, market access strategies, clinical evidence requirements, and, critically, how products are marketed and communicated to healthcare professionals and procurement teams. Companies that treat the IVDR solely as a regulatory burden will lose market position to competitors that leverage the new framework as a marketing differentiator.

The IVDR entered application on May 26, 2022, but transition timelines have been extended multiple times. As of 2026, the extended transition periods allow certain devices to continue to be marketed under legacy IVDD certificates, with deadlines stretching to May 2027 for higher-risk devices and May 2028 or 2029 for some lower-risk categories, depending on classification and Notified Body availability. However, all new devices entering the EU market must comply with the IVDR from the outset.

As a medical device marketing agency based in Nashville working with global diagnostic companies, we help manufacturers navigate the intersection of IVDR compliance and effective market communication. This guide covers the strategic marketing implications of the IVDR and how companies can turn regulatory requirements into competitive advantages.

Understanding the IVDR's Impact on Marketing

The New Classification System

The IVDD used a relatively simple list-based classification approach. Annex II listed higher-risk devices, and everything else was effectively self-certified. The IVDR replaces this with a risk-based classification system modeled on the Global Harmonization Task Force (now IMDRF) framework:

Class A: Lowest risk. General laboratory devices, specimen receptacles, buffer solutions. Self-assessment is still permitted for most Class A devices.
Class B: Moderate risk. Devices for clinical chemistry, hematology, and other routine testing where incorrect results pose moderate risk. Requires Notified Body assessment for most devices.
Class C: Higher risk. Devices for blood typing, companion diagnostics, screening for infectious diseases. Requires Notified Body assessment with more extensive clinical evidence.
Class D: Highest risk. Devices for blood screening (HIV, hepatitis, blood grouping for transfusion), detection of high-risk transmissible agents. Requires Notified Body assessment plus, in many cases, EU Reference Laboratory verification.

The marketing impact is substantial. Under the IVDD, an estimated 80% of IVDs were self-certified by manufacturers. Under the IVDR, approximately 80% now require Notified Body involvement. This shift means more rigorous clinical evidence requirements, longer time-to-market, and higher development costs, all of which affect how and when products can be marketed.

Clinical Evidence Requirements

The IVDR dramatically increases clinical evidence requirements for diagnostic devices. Under the IVDD, many IVDs could be placed on the market with limited clinical data. The IVDR requires:

Clinical performance studies: Prospective studies demonstrating diagnostic sensitivity, specificity, and overall performance in the intended population
Clinical evidence reports: Comprehensive compilations of all available clinical evidence, including literature reviews, experience from clinical use, and original clinical performance data
Performance evaluation plans: Structured plans for ongoing performance monitoring throughout the device lifecycle
Post-market performance follow-up (PMPF): Systematic post-market surveillance of clinical performance, analogous to post-market clinical follow-up for medical devices under the MDR

For marketers, these requirements create both challenges and opportunities. The challenge is that marketing claims must be precisely aligned with the clinical evidence submitted to Notified Bodies. The opportunity is that companies with robust clinical evidence programs can differentiate their products from competitors still struggling with IVDR compliance.

IVDR Marketing Strategy: Turning Compliance Into Competitive Advantage

Positioning Around IVDR Compliance

As the transition period continues and many devices remain in regulatory limbo, companies that achieve full IVDR compliance early can use their regulatory status as a marketing differentiator. Consider these positioning strategies:

"IVDR Certified" messaging: Prominently communicating your device's IVDR certification status signals quality, reliability, and commitment to patient safety. For procurement teams in European hospitals and laboratories, IVDR compliance is increasingly becoming a purchasing prerequisite.

Clinical evidence leadership: Position your robust clinical evidence package as a differentiator. Where competitors rely on legacy data or historical performance claims, your prospective clinical performance studies demonstrate a commitment to evidence-based diagnostics.

Continuity assurance: Many laboratories are concerned about supply disruption as devices lose their legacy certifications. Marketing that emphasizes your uninterrupted market presence and forward-looking compliance timeline provides procurement teams with purchasing confidence.

Transparency in classification: Clearly communicating your device's IVDR classification, CE marking status, and the specific Notified Body involved builds trust with sophisticated European buyers who understand the regulatory landscape.

Content Strategy for IVDR Markets

A comprehensive medical device marketing guide covers content strategy foundations, but IVDR markets require specific content approaches:

Regulatory education content: Many of your customers, laboratory directors, pathologists, and clinical scientists, are navigating the IVDR transition alongside you. Creating educational content that helps them understand IVDR implications for their laboratories positions your company as a knowledgeable partner, not just a product supplier. Topics include: how IVDR reclassification affects device availability in their laboratory, what IVDR means for laboratory-developed tests (LDTs), and how to evaluate the regulatory status of products from different suppliers.

Clinical evidence summaries: Provide accessible summaries of your clinical performance data. European laboratory professionals are increasingly requesting evidence packages as part of procurement evaluation. Making this evidence easily accessible (while protecting proprietary detail) demonstrates confidence in your product's clinical performance.

Transition timeline communications: Regular updates about your IVDR transition timeline for each product in your portfolio keep existing customers informed and reassure prospective customers about product availability. Consider quarterly regulatory status newsletters or a dedicated section on your website.

Comparison and selection guides: Help laboratory professionals evaluate IVDs by providing objective selection criteria that align with IVDR requirements: clinical performance data quality, post-market surveillance commitments, and Notified Body assessment outcomes.

Digital Marketing in European IVD Markets

Digital marketing for IVD products in European markets requires careful attention to regional differences, regulatory constraints, and audience behavior:

Website compliance: Your European-facing website and marketing materials must comply with IVDR labeling requirements. This includes accurate display of the UDI-DI (Unique Device Identification, Device Identifier), proper use of the CE marking symbol, clear identification of the Notified Body number, and links to the Summary of Safety and Performance (SSP) in EUDAMED when available.

Multi-language requirements: EU member states require labeling and instructions for use in their official languages. Marketing materials should be available in the major European languages relevant to your target markets. This is not just translation; it requires localization that accounts for different healthcare systems, laboratory workflows, and procurement processes.

Healthcare SEO for European markets: An effective healthcare SEO strategy for IVD products must account for language-specific search behavior, country-specific domain preferences (many European healthcare professionals search on local domains), and the specific terminology used in different national laboratory traditions.

LinkedIn for European laboratory professionals: LinkedIn is the most effective professional social platform across Europe for reaching laboratory directors, clinical scientists, pathologists, and procurement professionals. Content should be posted in English (the lingua franca of European science) but supplemented with localized campaigns in German, French, Spanish, and Italian for key markets.

IVDR Implications for Specific IVD Categories

Companion Diagnostics

Companion diagnostics (CDx) face particularly significant IVDR implications. Under the IVDR, companion diagnostics are classified as Class C devices, requiring Notified Body assessment with specific attention to the drug-diagnostic linkage. Marketing implications include:

Marketing messaging must clearly communicate the approved drug-diagnostic pairing
Clinical evidence must include the diagnostic's performance in the context of the drug's clinical trials
Promotional materials must be coordinated with pharmaceutical marketing teams to ensure consistency
IVDR compliance timelines for CDx may affect drug launch strategies in Europe

Laboratory-Developed Tests (LDTs)

The IVDR's treatment of laboratory-developed tests is one of its most contentious provisions. Article 5(5) of the IVDR establishes that health institutions may manufacture and use IVDs in-house under specific conditions, but these devices are not exempt from the IVDR's safety and performance requirements. Marketing implications include:

Commercial IVD manufacturers can position their products as validated, CE-marked alternatives to in-house developed tests, emphasizing regulatory compliance, standardized performance, and reduced liability for the laboratory
Content marketing that addresses the regulatory burden of IVDR compliance for LDTs can drive conversion from in-house testing to commercial products
Educational content about IVDR Article 5(5) requirements helps laboratories understand their obligations and may accelerate adoption of commercial alternatives

Point-of-Care and Near-Patient Testing

Point-of-care testing (POCT) devices face reclassification under the IVDR that may increase their regulatory burden. Many POCT devices previously self-certified under the IVDD now require Notified Body assessment. Marketing strategies for POCT in the IVDR era should:

Emphasize the quality assurance benefits of using IVDR-compliant POCT devices versus unregulated alternatives
Provide training and quality management content that helps decentralized testing sites maintain IVDR compliance
Position IVDR compliance as a patient safety differentiator in procurement discussions with hospital administrators and laboratory oversight committees

Market Access Strategy Under the IVDR

Notified Body Strategy

The number of Notified Bodies designated under the IVDR remains significantly lower than under the IVDD. As of early 2026, fewer than 10 Notified Bodies are fully designated for IVDR assessments, compared to over 20 under the IVDD. This bottleneck creates real market access challenges and marketing implications:

Companies with established Notified Body relationships can bring products to market faster, and this speed advantage is marketable
The Notified Body scarcity means some competitors will face delays or gaps in their product portfolios, creating market share opportunities for companies with secured capacity
Communication about your Notified Body relationship and assessment timeline provides procurement confidence

EUDAMED and Market Transparency

The European Database on Medical Devices (EUDAMED) is designed to increase transparency across the IVD market. When fully functional, EUDAMED will contain device registration information, Notified Body certificates, clinical investigations data, vigilance reports, and market surveillance information. Marketing implications include:

Product information in EUDAMED will be publicly accessible, making it imperative that all information is accurate, current, and aligned with marketing claims
Competitors' regulatory status and vigilance history will also be visible, enabling more informed competitive positioning
Proactive transparency, making your EUDAMED data easily accessible and well-organized, can be a trust differentiator

Post-Market Surveillance and Marketing Alignment

PMPF as a Marketing Asset

The IVDR's post-market performance follow-up (PMPF) requirements generate ongoing clinical performance data. Smart marketing strategies treat PMPF as both a regulatory obligation and a marketing asset:

PMPF data demonstrating sustained clinical performance over time strengthens your product's clinical evidence narrative
Proactive sharing of post-market performance summaries with customers (within regulatory boundaries) builds trust and demonstrates accountability
Trends identified through PMPF can inform product improvement messaging and next-generation product positioning

Vigilance Reporting and Brand Protection

The IVDR strengthens vigilance reporting requirements. How your company handles adverse events and field safety corrective actions (FSCAs) has direct marketing implications. Transparent, timely communication during vigilance events protects brand reputation. Companies that handle FSCAs poorly suffer lasting reputation damage in the relatively small European IVD market.

Regional Market Considerations

Key European Markets

IVDR marketing strategies must account for significant market differences across Europe:

Germany: The largest European IVD market. Strong laboratory infrastructure, evidence-driven procurement, active KOL community. German-language content and relationships with key institutions (DKFZ, Max Planck Institutes, university hospital laboratories) are essential.
France: Centralized healthcare purchasing through hospital groups (GHTs). Marketing must address group procurement dynamics. The Haute Autorite de Sante (HAS) influences coverage and reimbursement decisions.
United Kingdom: Post-Brexit, the UK follows the UKCA marking system under MHRA oversight rather than the IVDR. Companies targeting both EU and UK markets need parallel regulatory and marketing strategies.
Italy and Spain: Growing IVD markets with increasing digitalization. Relationship-based selling remains important. Local distributor partnerships often drive market access.
Nordic countries: Collaborative purchasing groups, strong emphasis on health technology assessment, and high digital maturity. Evidence-based marketing resonates strongly.

Beyond Europe: IVDR's Global Influence

The IVDR's influence extends beyond Europe. Many countries reference EU regulatory frameworks when developing their own IVD regulations. Companies that build marketing programs around IVDR compliance may find these assets applicable in other markets, including Australia (TGA), Canada (Health Canada), and parts of Asia and Latin America.

Building an IVDR-Ready Marketing Organization

Cross-Functional Alignment

Effective IVDR marketing requires tight coordination between marketing, regulatory affairs, quality assurance, and clinical affairs teams. Key alignment areas include:

Claims management: Every marketing claim must be traceable to supporting clinical evidence in the technical documentation. Establish a claims matrix that maps marketing messages to specific evidence sources.
Material review processes: Update your promotional material review process to include IVDR-specific checkpoints: classification accuracy, CE marking display, UDI compliance, and alignment with the declared intended purpose.
Training for marketing teams: Marketing professionals need baseline IVDR knowledge. Invest in training that helps marketers understand the regulatory framework well enough to create compliant materials without requiring regulatory review of every communication.

Technology and Systems

IVDR-compliant marketing operations benefit from technology investments:

Digital asset management systems that maintain version-controlled marketing materials aligned with current regulatory status
Claims management databases that link marketing statements to clinical evidence
CRM systems configured to track the regulatory status of each product by market, enabling targeted communications based on availability
Marketing automation platforms that manage multi-language, multi-market campaigns with regulatory compliance guardrails

IVDR Impact on Digital Health and Software IVDs

Software as an IVD

The IVDR brings standalone software, including laboratory information management systems (LIMS) with diagnostic functionality, clinical decision support software, and AI-powered diagnostic algorithms, under its regulatory scope. Software that was previously unregulated or self-certified under the IVDD may now require Notified Body assessment under the IVDR. For marketing teams, this creates both challenges and opportunities. Products with IVDR certification for their software components can differentiate against competitors still operating under legacy certifications or outside regulatory scope. Marketing should clearly communicate the regulatory status of software components, including the specific IVDR classification, the clinical performance evidence supporting software claims, and the ongoing validation processes that ensure continued performance.

AI and machine learning-based IVDs face particular IVDR challenges. The regulation's requirements for clinical evidence and performance validation must account for the dynamic nature of ML algorithms that may evolve with new training data. Marketing claims about AI diagnostic performance must be supported by validation studies conducted on representative European patient populations, using clinically relevant performance metrics. The Common Specifications that the European Commission may publish for specific IVD categories could impose additional requirements on AI-based devices, and marketing teams should monitor these developments closely to ensure continued claim compliance.

Cybersecurity and Data Protection

The IVDR's general safety and performance requirements include cybersecurity provisions for IVDs with electronic programmable systems and connected devices. Marketing materials for connected IVDs should address cybersecurity measures as a value proposition, particularly for laboratory customers concerned about data integrity, network security, and compliance with the EU's NIS2 Directive. Position your device's cybersecurity architecture as a feature that protects patient data and ensures diagnostic reliability, not just as a regulatory compliance checkbox. Include information about your cybersecurity risk management process, vulnerability disclosure policy, and software update mechanisms in marketing materials directed at laboratory IT teams and procurement professionals.

Trade Show and Conference Strategy for IVDR Markets

Key European Diagnostics Events

Marketing at European diagnostics conferences requires IVDR-aware messaging and positioning. Key events include Medica/Compamed in Dusseldorf (the world's largest medical trade fair, with a significant IVD presence), the IFCC WorldLab Congress (the premier clinical chemistry and laboratory medicine event), EuroMedLab (the European Federation of Clinical Chemistry and Laboratory Medicine conference), and specialty-specific congresses in areas like molecular diagnostics, microbiology, and pathology. Your conference presence should showcase IVDR compliance achievements, present clinical performance data in poster and oral presentation formats, and provide educational content about IVDR implications for laboratory operations. Pre-conference marketing should target attendees with IVDR-relevant content that positions your company as a knowledgeable partner in the regulatory transition.

Post-conference follow-up campaigns should segment leads by their IVDR awareness level and provide tailored content: basic IVDR education for those new to the regulation, detailed clinical evidence packages for those in active evaluation, and implementation support resources for those ready to adopt. This segmented approach ensures that your conference investment generates qualified pipeline across the entire customer journey.

The IVDR transition is a once-in-a-generation strategic opportunity for diagnostic companies. Those that approach it solely as a compliance exercise will bear costs without capturing the competitive advantages that early, high-quality IVDR certification provides. Those that integrate IVDR compliance into their marketing strategy, using superior clinical evidence, regulatory leadership, and customer education as differentiators, will emerge from the transition period with strengthened market positions across Europe and beyond.